CBD and Liver Health: What You Need to Know

The increasing global popularity of Cannabidiol (CBD) has led to widespread use for various health conditions. While often perceived as benign, emerging evidence suggests a potential for CBD to impact liver function, specifically in the context of Drug-Induced Liver Injury (DILI). This article delves into the current understanding of CBD's effects on the liver, its interaction with Hepatitis C Virus (HCV), and the critical considerations for managing CBD-associated hepatotoxicity.

CBD and Hepatitis C Virus (HCV)

Preliminary research indicates that CBD may possess antiviral properties against Hepatitis C Virus (HCV). In vitro studies have shown that CBD can inhibit HCV replication. Specifically, at a concentration of 10 μM, CBD demonstrated an 86.4% inhibition of HCV replication, with an EC50 value of 3.163 μM in dose-response assays. These promising findings suggest that CBD could be a potential candidate for further therapeutic development and application in the treatment of HCV. However, it is important to note that CBD did not show similar activity against Hepatitis B Virus (HBV) in these preliminary screenings.

Understanding Drug-Induced Liver Injury (DILI)

Drug-Induced Liver Injury (DILI) is a significant concern in pharmacology and clinical practice. It is biochemically categorised into three main types: hepatocellular, cholestatic, or mixed, based on the R value (a ratio of serum ALT and ALP). This classification helps identify the offending medication, understand the mechanism of liver damage, guide investigations, and provide prognostic insights. DILI diagnosis can be challenging due to its varied presentations and the lack of definitive diagnostic markers. It often requires a thorough review of all medications, recreational substances, herbal products, and dietary supplements, with a focus on the onset, dose, duration of use, and prior exposures.

CBD-Associated Hepatotoxicity: An Overview

Despite the common perception of CBD's safety, there is growing evidence linking its use to elevated liver enzymes (LEs) and DILI. A recent meta-analysis revealed that CBD use is associated with a higher risk of LE elevation (OR = 5.85) and DILI (OR = 4.82) compared to placebo. These effects have been observed in both medical and healthy populations. Key risk factors identified include high-dose CBD use and the concomitant use of antiepileptic drugs (AEDs). While most reported cases of elevated LEs resolved with dose reduction or discontinuation of CBD, the potential for progression to severe DILI or liver failure if CBD were continued at the same dose remains unknown. The incidence of DILI associated with CBD (2.96%) suggests it can be classified as a common adverse drug reaction. Some individuals also experienced elevated bilirubin levels, though these generally remained below the Upper Limit of Normal (ULN) and resolved upon intervention.

Pathophysiology of CBD-Related Hepatotoxicity

The exact mechanisms underlying CBD-associated hepatotoxicity are still being elucidated. DILI can stem from intrinsic (predictable, dose-dependent) or idiosyncratic (less predictable, influenced by individual factors) mechanisms. Current understanding leans towards idiosyncratic DILI being an immunologic phenomenon, possibly influenced by genetic susceptibility, such as specific human leukocyte antigen (HLA) alleles. Mitochondrial dysfunction may also play a role. CBD's complex pharmacodynamics, involving interactions with various receptors and enzymes (including cytochrome P450 enzymes), contribute to its multifaceted effects. It regulates numerous genes involved in lipid and drug metabolism, and its modulation of CYP enzymes can impact the metabolism of other substances. This complex interplay likely contributes to the observed variability in liver responses to CBD.

Risk Factors for CBD-Related Hepatotoxicity

Several factors can increase the risk of CBD-associated liver injury:

Route of Administration

Currently, all reported cases of DILI have been associated with oral CBD oil. Inhaled CBD bypasses first-pass hepatic metabolism, potentially reducing the risk of hepatotoxicity. However, more research is needed to confirm this for other administration routes.

CBD Dose

High-dose CBD use (> 1000 mg/day) is a significant risk factor for LE elevations and DILI. However, the relationship is not strictly dose-dependent, as some individuals have experienced DILI at moderate doses, while others have not experienced issues even at very high doses. Low doses of CBD (< 300 mg) in adults have not been associated with hepatotoxicity, suggesting that most individuals using CBD at lower doses are at a lower risk, provided they are not taking interacting medications.

Concomitant Medications

The risk of CBD-associated hepatotoxicity appears to be elevated when used concurrently with certain medications, particularly AEDs like valproic acid (VPA) and clobazam (CLB). VPA use in conjunction with CBD significantly increases the odds of LE elevations and DILI. While the exact mechanism for VPA interaction is unclear, it may involve pharmacodynamic effects. CBD's interaction with CYP2C19 can increase plasma levels of clobazam's active metabolite, norclobazam, which could contribute to adverse effects. Other AEDs, while potentially hepatotoxic themselves, were less frequently reported in cases of CBD-associated DILI unless co-administered with VPA or CLB. The use of acetaminophen and hormonal birth control has also been noted in some cases, but their direct contribution to CBD-related DILI is less clear.

Genetics

Genetic factors are likely to play a role in an individual's susceptibility to CBD-associated hepatotoxicity. While not yet routinely used in clinical practice, genetic variations, such as those in HLA alleles or mitochondrial function, may predispose individuals to liver injury. Research is ongoing to identify specific genetic markers that could predict an individual's risk.

Abnormal Baseline Liver Enzymes

Individuals with elevated baseline liver enzymes appear to be at a higher risk for further LE elevations when taking CBD. Studies suggest a significant proportion of cases with CBD-associated LE elevations or DILI occurred in individuals with baseline LEs between 1 and 3 × ULN. Close monitoring is recommended for individuals with abnormal baseline liver enzymes initiating CBD therapy.

History of Chronic Liver Disease

Research on CBD's impact in individuals with pre-existing chronic liver diseases is limited but suggests potential therapeutic benefits in conditions like metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), possibly due to its anti-inflammatory and antioxidant effects. Preclinical studies in animal models indicate CBD may reduce liver inflammation, fibrosis, and lipid accumulation. While human evidence is less robust, some studies suggest improved outcomes in patients with chronic liver conditions. However, caution and further research are warranted.

Age

Current literature on CBD-associated hepatotoxicity primarily focuses on populations under 50. Age has not been identified as a significant risk factor in these studies. However, given the increasing CBD consumption among older adults, further research is needed to assess potential risks in this demographic.

Clinical Presentation and Time Course of CBD-Associated Hepatotoxicity

Many individuals experiencing CBD-associated hepatotoxicity may be asymptomatic. When symptoms do occur, they can be varied. Rash, including macular, papular, erythematous, or follicular, has been reported, particularly with rapid initiation of high-dose CBD. Liver injury associated with eosinophilia and rash may indicate a severe immunoallergic reaction requiring further investigation. The biochemical pattern of CBD-associated DILI is predominantly hepatocellular, although some mixed patterns have been observed. LE elevations typically occur during the initial phase of CBD use, often within the first 5 weeks, but can sometimes be observed up to 18 months after initiation, especially in those also taking VPA.

Prognosis and Management of CBD-Associated Hepatotoxicity

Despite the observed frequency of LE elevations and DILI with CBD use, no severe cases meeting the criteria for Hy's law (indicating severe liver injury) have been reported. The majority of cases resolve with interventions such as CBD discontinuation or dose reduction, or by adjusting the dosage of concomitant hepatotoxic medications. In some instances, LEs have resolved spontaneously with continued CBD use. Resolution typically occurs within 2 weeks to 4 months after intervention. However, it is crucial to acknowledge that many individuals using non-prescription CBD may not have their LEs monitored or disclose their use to healthcare providers, potentially delaying diagnosis and management. The duration of clinical trials and withdrawal criteria can also limit the assessment of long-term outcomes and the potential progression to chronic liver disease.

Practical Recommendations for Managing CBD-Associated Hepatotoxicity

Healthcare providers should be aware of the potential for CBD-associated hepatotoxicity and implement appropriate management strategies:

• Monitoring: For individuals at increased risk of CBD-associated hepatotoxicity (e.g., those taking > 300 mg/day, or with risk factors), baseline monitoring of liver enzymes (ALT, AST, ALP, bilirubin, INR) is recommended, followed by regular checks (e.g., every 2 weeks for the first 6 weeks, then monthly for the first 6 months).
• Dose Adjustment: If LE elevations are sustained but mild, reducing the CBD dosage by 50% or adjusting other potentially hepatotoxic medications may be considered. Re-evaluation of LEs after 7 days is advised.
• Risk Assessment: Individuals on > 300 mg/day of oral CBD for > 3 months without baseline risk factors are likely at low risk. Clinical judgment should guide the need for further blood work.
• Patient Education: Educate patients about the potential risks of CBD, especially concerning liver health, and encourage disclosure of CBD use to their healthcare providers.
• Concomitant Medication Review: Pay close attention to concomitant medications, particularly AEDs, when prescribing or advising on CBD use.

Conclusion

While CBD shows promise in certain therapeutic areas, including potential antiviral effects against HCV, its association with liver enzyme elevations and DILI cannot be ignored. Healthcare providers must remain vigilant, assess individual risk factors, and implement appropriate monitoring and management strategies to ensure patient safety. Further research is essential to fully elucidate the mechanisms of CBD-induced hepatotoxicity and to establish clear guidelines for its safe and effective use.